EMA panel recommends against Portola's clot prevention drug

(Reuters) – A panel of European Medicines Agency on Friday recommended against granting marketing approval to Portola Pharmaceuticals Inc’s oral blood thinner, saying the benefits of the drug did not outweigh risks.


Source: Reuters Medical News

Leave a Reply

Your email address will not be published. Required fields are marked *